DYN: Expect major regulatory and clinical milestones in DMD and DM1, with commercial launch preparations underway
The company highlighted its differentiated genetic medicine platform, strong clinical data in DMD and DM1, and readiness for commercial launch. Key catalysts include a major regulatory decision in January, pivotal DM1 data in Q1, and expansion into FSHD and additional DMD subgroups.Based on Dyne Th…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.